Article
Monitoring multiple myeloma by quantification of recurrent mutations in serum.
Haematologica - 1 Jul 2017
Rustad Even Holth, Coward Eivind, Skytøen Emilie R, Misund Kristine, Holien Toril, Standal Therese, Børset Magne, Beisvag Vidar, Myklebost Ola, Meza-Zepeda Leonardo A, Dai Hong Yan, Sundan Anders, Waage Anders
Abstract excerpt
Circulating tumor DNA is a promising biomarker to monitor tumor load and genome alterations. We explored the presence of circulating tumor DNA in multiple myeloma patients and its relation to disease activity during long-term follow-up. We used digital droplet polymerase chain reaction analysis to monitor recurrent mutations, mainly in mitogen activated protein kinase pathway genes NRAS, KRAS and BRAF Mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.